Basic information Safety Supplier Related

Etrolizumab

Basic information Safety Supplier Related

Etrolizumab Basic information

Product Name:
Etrolizumab
Synonyms:
  • Etrolizumab
  • Research Grade Etrolizumab(DHC98803)
  • rhuMAb Beta7
  • Etrolizumab (anti-α4β7)
  • Research Grade Etrolizumab
CAS:
1044758-60-2
MW:
0
Mol File:
Mol File
More
Less

Etrolizumab Chemical Properties

storage temp. 
Store at -20°C
form 
Liquid
color 
Colorless to light yellow
More
Less

Etrolizumab Usage And Synthesis

Uses

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with Ki values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD)[1][2].

in vivo

Etrolizumab (rhuMAb Beta7; 5 mg/kg; i.v.; once; normal female BALB/c mice) decreases β7 integrins on T lymphocytes[2].
Etrolizumab (200 μg (100 μL); i.p.; once) inhibits lymphocyte homing in the CD45RBhigh T cell-reconstituted SCID mouse model of colitis[2].

Animal Model:Normal female BALB/c mice (17-21 g)[2]
Dosage:5 mg/kg
Administration:Intravenous injection; once
Result:Had 98.3% of intraepithelial CD8+ T-cell β7 integrin receptors and 90.0% of intraepithelial CD4+ T-cell β7 integrin receptors after 24 h.
Animal Model:SCID mouse model of colitis[2]
Dosage:200 μg (100 μL)
Administration:Intraperitoneal injection; once
Result:Blocked lymphocyte recruitment and homing to the inflamed colon.

IC 50

α4β7; αEβ7

References

[1] Tang MT, et, al. Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti-β7 integrin therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47(11):1440-1452. DOI:10.1111/apt.14631
[2] Stefanich EG, et, al. A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol. 2011 Apr;162(8):1855-70. DOI:10.1111/j.1476-5381.2011.01205.x

EtrolizumabSupplier

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Beijing Solarbio Science & Tecnology Co., Ltd.
Tel
010-50973130 18101056239
Email
3193328036@qq.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com